Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
112.8 BRL | +0.61% | -3.42% | +21.18% |
05-23 | Some of the biggest splits in Corporate America | RE |
05-22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.86 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.18% | 52.36B | - | ||
+7.01% | 217B | B | ||
+11.01% | 190B | B- | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.48% | 64.59B | A- | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.6B | - | ||
+19.95% | 30.31B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- E1WL34 Stock
- Ratings Edwards Lifesciences Corporation